{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061958","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.377388+00:00","generated_at":"2026-06-01T22:51:08.674925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortress Biotech Q1 net loss narrows to $17.7M; FDA accepts DFD-29 NDA for rosacea","bullets":["Consolidated net revenue $13.0M, all from dermatology products, up 7% YoY driven by Qbrexza and Accutane.","Net loss attributable to common stockholders $(17.7)M ($1.03/share) vs $(23.5)M ($3.47/share) in Q1 2023.","Cash and equivalents $85.8M as of March 31, up from $83.4M; includes $11M January direct offering.","FDA accepted DFD-29 NDA with PDUFA date Nov 4, 2024; potential only oral therapy for rosacea lesions and erythema.","Triplex CMV vaccine Phase 2 for HIV/CMV fully enrolled; topline data Q4 2024; liver transplant trial dosed first patient."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061958","json":"https://secwatch.observer/filing/0001104659-24-061958.json","markdown":"https://secwatch.observer/filing/0001104659-24-061958.md","text":"https://secwatch.observer/filing/0001104659-24-061958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/0001104659-24-061958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/tm2414584d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:51:08.674925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80ae50aef1b34901d0f4e75c55ac25d7245dec6c","claim":"Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/0001104659-24-061958-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}